Pupillary Dilation Reflex (PDR) Evaluation During General Anesthesia
1 other identifier
interventional
41
1 country
1
Brief Summary
In this study, the pupillary dilation reflex is measured as a nociceptive indicator during elective abdominal surgery under general anesthesia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable pain
Started Oct 2016
Shorter than P25 for not_applicable pain
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2016
CompletedFirst Submitted
Initial submission to the registry
October 20, 2016
CompletedFirst Posted
Study publicly available on registry
October 24, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2017
CompletedMay 21, 2018
May 1, 2018
6 months
October 20, 2016
May 16, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Pupillary Reflex Dilation
Pupillary Reflex Dilation is measured four times intraoperatively as a possible indicator of success of analgesia
Perioperative phase
Secondary Outcomes (2)
Patient Movement
Perioperative phase
Vital signs
Perioperative phase
Study Arms (1)
Pupil dilation reflex measurement
EXPERIMENTALFour measurements of PDR during surgery at standardized times
Interventions
Pupillometry (PDR) at four standardized times perioperatively * after induction, before opioid administration * after opioid administration, steady state * surgical incision * end of procedure
Eligibility Criteria
You may qualify if:
- Scheduled abdominal surgery
- ASA I-II
You may not qualify if:
- History of eye deformity, invasive ophthalmologic surgery, impaired pupil reflex in advance
- Kown cranial nerve(s) deficit
- Infection of the eye
- Predicted difficult airway management (DAF Guidelines)
- Chronic opioid use (\>3 months)
- Ongoing treatment with beta-blockers, dopamine antagonists, topical atropine
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University hospital Antwerp
Edegem, Antwerp, 2650, Belgium
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Robert Slappendel, MD, PhD
University Hospital, Antwerp
- PRINCIPAL INVESTIGATOR
Michiel Baeten, MD
University Hospital, Antwerp
- PRINCIPAL INVESTIGATOR
Davina Wildemeersch, MD
University Hospital, Antwerp
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
October 20, 2016
First Posted
October 24, 2016
Study Start
October 1, 2016
Primary Completion
April 1, 2017
Study Completion
May 1, 2017
Last Updated
May 21, 2018
Record last verified: 2018-05
Data Sharing
- IPD Sharing
- Will not share